HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calcium, vitamin D in older women

This article was originally published in The Tan Sheet

Executive Summary

Postmenopausal women did not experience a drop in blood pressure or hypertension risk after seven years of calcium plus vitamin D3 supplementation, says a study published in the November issue of the American Heart Association's Hypertension journal. In the randomized, placebo-controlled trial, researchers led by Karen L. Margolis of Minneapolis-based HealthPartners Research Foundation assigned 36,282 subjects to take 1,000 mg of elemental calcium plus 400 IU of vitamin D3 daily or a placebo. The report says the trial was longer than other studies and lost few subjects during follow-up. The large subject pool allowed researchers to study subgroups hypothesized to benefit more from calcium and vitamin D, including blacks, Asians and hypertensive women. No subgroup displayed signs of benefiting from the supplement, the study says. A study of U.S. men and women published July 2007 found an inverse link between vitamin D levels and blood pressure (1"The Tan Sheet" Aug. 13, 2007, p. 10)

You may also be interested in...



Vitamin D Levels Inversely Associated With Hypertension – Study

Low levels of vitamin D were associated with high blood pressure among a large sample of the U.S. population, according to the results of a study in the July issue of the American Journal of Hypertension

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel